Status epilepticus associated with sertindole.
Sinn
D-I
DI
Chu
K
K
Jung
K-H
KH
Park
K-I
KI
Nam
H
H
Lee
S K
SK
D000927:Anticonvulsants / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D008875:Middle Aged; D010672:Phenytoin / Q000627:therapeutic use; D044405:Receptor, Serotonin, 5-HT2C / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy; D012701:Serotonin / Q000378:metabolism; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D013226:Status Epilepticus / Q000139:chemically induced* / Q000503:physiopathology; D016896:Treatment Outcome
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D007093:Imidazoles; D007211:Indoles; D044405:Receptor, Serotonin, 5-HT2C; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists; D012701:Serotonin; D010672:Phenytoin; C066304:sertindole; D006220:Haloperidol